Keywords
Bioassay selection
Bioactivity
Natural products
Drug discovery
Blue biotechnology
Bioactivity-guided purification
Validation
Preclinical trials
Biodiscovery
AbbreviationsABTS/TEAC
2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)/Trolox®-Equivalent Antioxidant Capacity
ADMET
absorption, distribution, metabolism, excretion, toxicity
AFST
antifungal susceptibility testing
CADD
computer-aided drug design
CC50
50 % cytotoxicity concentration
CLSI
Clinical and Laboratory Standards Institute
COST
European Cooperation in Science and Technology
CTA
cell transformation assays
CUPRAC
CUPric Reducing Antioxidant Capacity
DPPH
2,2-Diphenyl-1-picrylhydrazyl
EC50
50% effective concentration
EFSA
European Food Safety Authority
EMA
European Medicines Agency
EUCAST
European Committee on Antimicrobial Susceptibility Testing
FDA
United States Food and Drug Administration
FMCA
fluorometric microculture cytotoxicity assay
GI50
50 % growth inhibition
GLP
good laboratory practice
HAT
hydrogen atom transfer
HIA
hemagglutination inhibition assay
HTS
high-throughput screening
LLPS
liquid-liquid phase separation
MALDI-TOF
matrix-assisted laser desorption ionization–time-of-flight mass spectrometry
MIC
minimum inhibitory concentration
MOI
multiplicity of infection
MBC
minimum bactericidal concentration
MTT
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide a yellow tetrazole that is reduced to purple formazan in living cells
MSPE
magnetic solid phase extraction
NAM
new approach methodology
OECD
Organisation for Economic Co-operation and Development
ORAC
oxygen radical absorbance capacity
PRA
plaque reduction assay
qPCR
quantitative real-time polymerase chain reaction
SPE
solid phase extraction
VRA
virus yield reduction assay
Comments (0)